London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

The agreement announced Wednesday brings GSK efimosfermin alfa, a Boston Pharmaceuticals drug that is ready for Phase 3 testing. In addition to metabolic dysfunction-associated steatohepatitis ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...